The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy
Authors
Keywords
-
Journal
Science China-Life Sciences
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-26
DOI
10.1007/s11427-021-2123-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The interaction of SET and protein phosphatase 2A as target for cancer therapy
- (2021) E.C. Dacol et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Loss of SET reveals both the p53-dependent and the p53-independent functions in vivo
- (2019) Ning Kon et al. Cell Death & Disease
- The multiple mechanisms that regulate p53 activity and cell fate
- (2019) Antonina Hafner et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers
- (2019) Yuanlong Ge et al. Protein & Cell
- A comprehensive and perspective view of oncoprotein SET in cancer
- (2018) Buuvee Bayarkhangai et al. Cancer Medicine
- Targeting PP2A in cancer: Combination therapies
- (2018) Sahar Mazhar et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer
- (2017) Xiaoning Yuan et al. ONCOLOGY REPORTS
- The “readers” of unacetylated p53 represent a new class of acidic domain proteins
- (2017) Donglai Wang et al. Nucleus
- The “readers” of unacetylated p53 represent a new class of acidic domain proteins
- (2017) Donglai Wang et al. Nucleus
- Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode
- (2016) Donglai Wang et al. NATURE
- Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential
- (2016) M-H Hung et al. ONCOGENE
- Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer
- (2015) Hao Liu et al. Oncotarget
- Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models
- (2014) Lays M Sobral et al. Molecular Cancer
- Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
- (2014) M. Janghorban et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease
- (2013) Guang Yu et al. NEUROBIOLOGY OF AGING
- Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells
- (2013) Kadir C. Akdemir et al. NUCLEIC ACIDS RESEARCH
- Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis
- (2012) Sahar A. Saddoughi et al. EMBO Molecular Medicine
- Fingolimod for Multiple Sclerosis
- (2012) Daniel Pelletier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
- (2011) I. Cristobal et al. HAEMATOLOGICA
- Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity
- (2011) Ji-Young Kim et al. NUCLEIC ACIDS RESEARCH
- Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
- (2011) C H Switzer et al. ONCOGENE
- ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ–PP2A
- (2011) G P Shouse et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More